Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.55 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030965 | 0.87 | OPRD1 (0.55) | OPRD1OPRK1OPRM1HRH1 | |
| SCHEMBL6030115 | 0.83 | HRH1 (0.51) | OPRD1OPRK1KDM1AMAPK1NR1H2 | |
| SCHEMBL6030481 | 0.80 | OPRD1 (0.42) | OPRD1OPRK1KDM1AMAPK1NR1H2 | |
| SCHEMBL6031015 | 0.80 | HRH1 (0.50) | OPRD1OPRK1KDM1AMAPK1NR1H2 | |
| SCHEMBL6030029 | 0.79 | HRH1 (0.56) | OPRD1OPRK1KDM1AMAPK1NR1H2 | |
| SCHEMBL6031742 | 0.79 | HRH1 (0.56) | OPRD1OPRK1KDM1ANR1H2GPR119 | |
| SCHEMBL6031453 | 0.79 | HRH1 (0.67) | OPRD1OPRK1KDM1AMAPK1NR1H2 | |
| SCHEMBL6031091 | 0.79 | HRH1 (0.48) | OPRD1OPRK1KDM1AMAPK1NR1H2 | |
| SCHEMBL6030410 | 0.77 | HRH1 (0.44) | OPRD1OPRK1KDM1AMAPK1NR1H2 | |
| SCHEMBL7895228 | 0.74 | OPRD1 (0.47) | OPRD1OPRK1MAPK1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148214-B1 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-12 | — | — | US | disclosed |
| US-7087595-B2 | Antihistaminic spiro compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-08 | — | — | US | disclosed |
| EP-1144411-B1 | ANTIHISTAMINIC SPIRO COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050026901-A1 | Antiallergens; vision disorders | JANSSENS FRANS EDUARD (BE) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026901-A1 | Antiallergens; vision disorders | UACA, LTB4R, HLA-B | OPRD1 1139/4885OPRK1 2005/4885KDM1A 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.